29 October 2024, Tbilisi, Georgia
www.sheniekimi.ge Tatia Gochadze
Pfizer Delivers One Billionth Pneumococcal Vaccine Dose in Global Public Health Milestone
In a significant advancement for global health, Pfizer recently announced the delivery of its one billionth pneumococcal conjugate vaccine (PCV) dose through a collaboration with Gavi, the Vaccine Alliance. This milestone, over a decade in the making, reflects joint efforts to close health equity gaps by providing life-saving vaccines to children in low- and lower-middle-income countries. Delivered to Ethiopia, the billionth dose exemplifies the impact of public-private partnerships on improving global health.
Good news:
through this long-standing collaboration between Pfizer and Gavi, one billion life-saving PCV vaccines have reached 57 low- and lower-middle-income countries and are estimated to have helped protect more than 300 million children. Since 2010, Pfizer’s PCVs have reached these Gavi-eligible nations, helping protect children from pneumococcal disease—a primary driver of pneumonia.
Pneumonia is the single largest infectious cause of death in children worldwide, killing 740,180 children under the age of 5 in 2019 alone. This staggering number accounted for 14% of all deaths among children under five and 22% of deaths in children aged 1 to 5 years. Addressing this preventable tragedy is central to Pfizer and Gavi’s partnership, which aims to combat this major public health threat by increasing vaccine accessibility.
“The delivery of one billion doses, particularly to regions that need it most, demonstrates a powerful commitment to protecting vulnerable children globally,” – states Professor Giorgi Pkhakadze, Chair of the “Public Health Institute of Georgia.”
Professor Pkhakadze, who was selected in 2019 as a member of the Independent Assessment Committee (IAC) of Gavi’s Pneumococcal Advanced Market Commitment (AMC), plays a crucial role in evaluating candidate vaccines for this program. The IAC, an impartial oversight body, assesses vaccines based on criteria such as target population, dosage, and product formulation, ensuring that those delivered through Gavi meet high standards.
“As a member of the Advance Market Commitment, I am proud to be part of an effort to save lives and build a healthier future for the next generation,” he shares. “The work does not stop here; we must continue advocating for equitable access.”
Global Health Implications
Pfizer’s billion-dose milestone highlights the success of health financing innovations like the Pneumococcal AMC, created in 2009 to support vaccine access in low-income countries. Through this initiative, Pfizer and its partners have delivered vaccines at highly subsidized prices, making them accessible to some of the world’s most at-risk children. As a result, global PCV coverage has increased from 10 percent in 2010 to 65 percent by 2023. However, this still falls short of the Immunization Agenda 2030’s target of 90 percent, emphasizing the need for continued commitment to vaccine accessibility.
“This achievement is not just about improving individual health outcomes” – Professor Pkhakadze emphasizes. “It’s about uplifting entire communities, reducing healthcare costs, and creating a more equitable world.” Immunization prevents severe disease and death while contributing to economic productivity and alleviating healthcare burdens, particularly in low-income countries.
Georgian Perspective
While Pfizer’s focus has been on Gavi-eligible countries, the implications resonate strongly in regions like Georgia, where equitable healthcare access remains a significant challenge. Georgia has made strides in expanding vaccination coverage, yet more work is needed to ensure timely access for all populations, whether urban, rural, affluent, or underserved. Professor Pkhakadze, who also leads the Public Health, Social, and Behavioral Science Department at “David Tvildiani Medical University” in Tbilisi, Georgia, reflects,
“In Georgia, our goal is to draw inspiration from these global partnerships and adapt strategies to enhance our national healthcare system. Vaccination is fundamental to building a healthier, more resilient population.”
Georgia’s efforts to adopt international healthcare standards, such as through Accreditation Canada initiatives, signal an increasing emphasis on quality, equity, and sustainability. Models like Gavi’s Pneumococcal AMC offer a roadmap for addressing health disparities and improving immunization coverage—a priority as Georgia works toward elevating its healthcare outcomes.
The Path Forward
Despite notable progress, the journey to health equity remains far from complete. Pfizer’s Accord for a Healthier World initiative, which aims to expand access to medicines and vaccines in 45 lower-income countries, represents an ambitious step toward achieving the World Health Organization’s (WHO) Immunization Agenda 2030 goals. This initiative seeks to bridge healthcare gaps by addressing system-level barriers to access, providing a sustainable approach to long-term health improvements in underserved regions.
“We have made progress, but we must not lose sight of what still needs to be done,”- Professor Pkhakadze states. “Ensuring vaccine accessibility worldwide will require continuous efforts, innovations, and collaborations.” Pfizer’s success with Gavi proves that strategic partnerships can create affordable and sustainable health solutions for children in low-income nations.
In celebrating this milestone, we are reminded of the power of unity and shared purpose in healthcare. For countries like Georgia, this achievement reinforces a commitment to fostering equitable healthcare access and underscores the global responsibility to protect our most vulnerable citizens—our children. By building on this milestone, Georgia and the global health community can work together to shape a future where preventable diseases like pneumonia no longer claim young lives.
📌 https://www.pfizer.com/news/press-release/press-release-detail/pfizer-supplies-one-billionth-pneumococcal-conjugated
📌
1. WHO. 2022. Pneumonia in children. Available at: https://www.who.int/news-room/fact-sheets/detail/pneumonia#:~:text=Pneumonia%20is%20the%20single%20largest,aged%201%20to%205%20years. Accessed September 2024.
2. Pfizer Inc. 2024. Data on file – Patient counts are estimates derived from Pfizer internal data sources” Pneumonia Prevalence and Associated Risk.
3. Alamneh YM, Adane F. Magnitude and Predictors of Pneumonia among Under-Five Children in Ethiopia: A Systematic Review and Meta-Analysis. J Environ Public Health. 2020 May 30;2020:1606783. doi: 10.1155/2020/1606783. PMID: 32565837; PMCID: PMC7277048. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7277048/#:~:text=5.-,Conclusion,to%20prevent%20those%20risk%20factors. Accessed September 2024.
4. Leka Lutpiatina, Lilis Sulistyorini, Ririh Yudhastuti, Hari Basuki Notobroto, Prediction of Toddlers Acute Respiratory Infection (ARI) to Become Pneumonia in Martapura Catchment Area, Banjar District, Indonesia, Global Pediatric Health, 10.1177/2333794X241227694, 11, (2024). Available at: https://onlinelibrary.wiley.com/doi/10.1155/2022/6497895#:~:text=In%20Ethiopia%2C%2044%2C000%20under%2Dfive,the%20postnatal%20period%20%5B5%5D. Accessed September 2024.
5. WHO. 2024. Pneumococcal Vaccination Coverage. Available at: https://immunizationdata.who.int/global/wiise-detail-page/pneumococcal-vaccination-coverage?CODE=Global&ANTIGEN=PCV3&YEAR= Accessed September 2024.
6. WHO. 2021. Implementing the Immunization Agenda 2030. Available at: https://www.who.int/teams/immunization-vaccines-and-biologicals/strategies/ia2030 Accessed September 2024.
7. Luyten J and Beutels P. 2016. The Social Value Of Vaccination Programs: Beyond Cost-Effectiveness. Health Affairs. 35(2). Available at: https://www.healthaffairs.org/doi/10.1377/hlthaff.2015.1088 Accessed September 2024.
8. Masia NA, Smerling J, Kapfidaze T et al. 2018. Vaccination and GDP Growth Rates: Exploring the Links in a Conditional Convergence Framework. World Development. 103;88-99. Available at: https://www.sciencedirect.com/science/article/abs/pii/S0305750X17303273 Accessed September 2024.
9. Chen C, Liceras FC, Flasche S et al. 2019. Effect and cost-effectiveness of pneumococcal conjugate vaccination: a global modelling analysis. The Lancet. 7(1);58-67. Available at: https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(18)30422-4/fulltext Accessed September 2024.
